Quotes 5-day view Delayed Nasdaq
05/19/2022
05/20/2022
05/23/2022
05/24/2022
05/25/2022
Date
7.25(c)
7.49(c)
7.3(c)
7.53(c)
7.34(c)
Last
935 309
608 739
635 381
562 810
702 735
Volume
+1.54% +3.31% -2.54% +3.15% -2.52% Change
Estimated financial data (e) (USD)
Sales 2022
-
-
-
Net income 2022
-183 M - -
Net cash position 2022
592 M - -
P/E ratio 2022
-3,34x
Yield 2022
-
Sales 2023
108 M - -
Net income 2023
-214 M - -
Net cash position 2023
743 M - -
P/E ratio 2023
-2,87x
Yield 2023
-
Capitalization
611 M 611 M -
EV / Sales 2022
-
EV / Sales 2023
-1,22x
Nbr of Employees
64
Free-Float
89,5%
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to enhace the lives of patients suffering from life-threatening viral infections. The Company is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The Company is...
Ratings of Atea Pharmaceuticals, Inc.
All news about ATEA PHARMACEUTICALS, INC.
05/10 ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. AQ
05/10 TRANSCRIPT : Atea Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 10, 2022CI
05/10 Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3.. CI
05/10 Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business.. AQ
05/03 Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma.. AQ
03/29 4794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..PU
03/29 4793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..PU
03/28 Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci.. AQ
03/02 JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutra.. MT
03/01 SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Per.. MT
02/28 ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. AQ
02/28 ATEA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..PU
02/28 Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31.. CI
02/28 TRANSCRIPT : Atea Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 28, 2022CI
02/28 ATEA PHARMACEUTICALS : Fourth Quarter 2021 Financial Results Conference Call PresentationPU
News in other languages on ATEA PHARMACEUTICALS, INC.
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
Atea plunges after COVID-19 treatment fails to help patients in study
Chart ATEA PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
7,34 $
Average target price
10,25 $
Spread / Average Target
39,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
